AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03313050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine
Study NCT03313050 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: Tetanus, diphtheria, acellular pertussis vaccine
Study NCT03313050 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polysaccharide
Description: 23-valent pneumococcal polysaccharide vaccine
Study NCT02722681 — intervention group
Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Collection of blood and urine samples taken during usual clinical management
Study NCT02722681 — intervention group
Intervention type: PROCEDURE
Intervention: Cerebrospinal fluid sampling
Description: Collection of cerebrospinal fluid samples taken during usual clinical management
Study NCT00836134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
Study NCT00836134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic infiltration
Description: Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
Study NCT01461174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200 mg tablet, single dose
Study NCT01461174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil or placebo, 5 mg tablet one per day, 15 days
Study NCT01461174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine or placebo, 10 mg tablet one per day, 15 days
Study NCT03915145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application
Description: Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
Study NCT03915145 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio tape application
Description: Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
Study NCT03915145 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
Study NCT04156555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
Study NCT03508492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Chloraprep® applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
Study NCT03508492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Nex Clorex 2% applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
Study NCT03041558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare+ (SC+)
Description: SafeCare intervention with the additional Healthy Relationships (HR) module
Study NCT03041558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SafeCare (SC)
Description: SafeCare intervention as usual
Study NCT02288585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: Plant sterols
Study NCT02288585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Placebo product
Study NCT01820442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Study NCT01820442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lofexidine-matching sugar pill
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study NCT03447158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15% Dextrose
Description: inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
Study NCT03447158 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
Study NCT02802605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin subcutaneus administration
Study NCT03303911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
Study NCT02388568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin plus Lifestyle Modification
Study NCT04270279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xueshuanxinmaining tablet
Description: A kind of Chinese patent medicine
Study NCT04270279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xueshuanxinmaining placebo
Description: The simulant of Xueshuanxinmaining tablet
Study NCT04270279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin tablets
Description: Be used when angina attack
Study NCT04270279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin tablets
Description: Be used when angina attack
Study NCT01461109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] CFPyPB
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
Study NCT02850471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
Study NCT02891070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS VH S/D 500 s-apr
Study NCT02891070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal Dural Sealant
Study NCT05282303 — intervention group
Intervention type: PROCEDURE
Intervention: CABG operation
Description: Efficacy of regional analgesia techniques in coronary artery bypass operations
Study NCT01701050 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
Study NCT03137745 — intervention group
Intervention type: OTHER
Intervention: thromboelastography
Description: thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
Study NCT01784822 — intervention group
Intervention type: DEVICE
Intervention: Zenapro™ Hybrid Hernia Repair Device
Description: Device will be placed during open or laparoscopic hernia repair.
Study NCT04308200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CO-OP approach
Description: There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies.
Study NCT04308200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NDT
Description: All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
Study NCT00795587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: variation of mannitol dose
Description: in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
Study NCT02205840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-614
Description: 1 drop in each eye
Study NCT02205840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye
Study NCT04017845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
Study NCT04017845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Precolonoscopy cleansing regimen
Description: Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
Study NCT04017845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Colonoscopy
Description: With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions \<25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
Study NCT04017845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histopathological examinations of screen-detected lesions
Description: Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: >10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
Study NCT04017845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tribenoside 400 mg + lidocaine 40 mg suppositories
Description: Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV (intravenous)
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 4)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 3)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (dose level 1)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (dose level 2)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (dose level 1)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (dose level 2)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV
Study NCT03509012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (dose level 1)
Description: radiation therapy
Study NCT03509012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (dose level 2)
Description: radiation therapy
Study NCT03509012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (hyperfractionated)
Description: radiation therapy
Study NCT02388568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus Lifestyle Modification
Study NCT04473417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga
Description: single dose administration after 10hr fasting
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 1)
Description: IV
Study NCT03509012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 2)
Description: IV
Study NCT03509012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (standard)
Description: radiation therapy
Study NCT05424055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
Study NCT04017845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment
Description: Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
Study NCT04548869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Administered intravenously
Study NCT03601884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal Health Program
Description: The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.
Study NCT03601884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients.
Study NCT03601884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients.
Study NCT04055493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 200Mg Oral Tablet
Description: 3 x 200 MG per os
Study NCT02465268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65-shLAMP DC with GM-CSF
Study NCT02465268 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: unpulsed PBMC and saline
Study NCT02465268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td
Description: All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
Study NCT02465268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02465268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65-flLAMP DC with GM-CSF
Study NCT05176132 — intervention group
Intervention type: OTHER
Intervention: Life style intervention (dietician+ physiotherapist)
Description: Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.
Study NCT05176132 — intervention group
Intervention type: OTHER
Intervention: Self management
Description: Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)
Study NCT05176132 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Control groups (BMI 20-25 and BMI 25-30)
Study NCT04526964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management curriculum
Description: The Intervention starts during inpatient phase after relocation of potential study participants from the intensive care unit to normal ward and after informed consent to participate. Those subjects assigned to the CGr by randomization code receive standard care at the respective center. Subjects assigned to the IGr received, in addition to standard care, a multi-modular self-management training carried out at the respective center. The content of the self-management training should be deepened and consolidated through a supplementary app. Training is performed during inpatient post-implant phase, as well as one refresher session about six weeks after discharge during regular outpatient follow-up. The intervention lasts 3 months, plus a 9-month follow-up per subject. The content of the self-management training is based on current evidence and was written in a curriculum to achieve the highest possible standardization, taking into account the center specifics.
Study NCT01450085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert
Description: Point of care GeneXpert
Study NCT01450085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LED Microscopy
Description: Point of care LED Microscopy
Study NCT03011684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: For ER Positive Randomization
Study NCT03011684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: For ER Positive Randomization
Study NCT03077516 — intervention group
Intervention type: DEVICE
Intervention: Mobi-C
Description: Device for cervical intervertebral disc replacement at one or two contiguous levels